GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 234.4 EUR | +0.60% |
|
+0.73% | -18.44% |
| 28/06 | Would you like some more inflation? |  |
| 28/06 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 12TCr | ||||||
| 11TCr | ||||||
| 2.59TCr | - | |||||
| 1.93TCr | - | |||||
| 1.56TCr | - |
- Stock Market
- Equities
- GMAB Stock
- GE9 Stock
- Charts Genmab A/S
- Sector Chart
